This study tested a treatment strategy for Ovarian cancer using autologous dendritic cells (DCs) and IL-2. The vaccine was well-tolerated by all patients, with common side effects being flu-like symptoms. Out of 10 patients, 3 had a long-lasting complete response without disease relapse for 38.2 to 83.0 months. Additionally, 5 patients achieved complete remission, 2 had stable disease, and 3 experienced disease progression. One patient with stable disease saw their tumor completely disappear after vaccination and maintained this response for 50.8 months. Overall, the combination of DCs and IL-2 immunotherapy appears to be safe and shows potential for long-term clinical responses against Ovarian cancer.
Patients with Ovarian cancer (OvCa) were treated with autologous dendritic cells (DCs) and IL-2 to evaluate the safety and feasibility of this therapeutic strategy and to characterize the antigen-specific immune alterations induced through this treatment.The vaccination was well tolerated. In patients with NED status and increased overall survival, DC vaccination induced tumor-related immunity, potentially associated with long-term clinical responses against OvCa.
The inclusion status after the initial therapy showed the maintenance of complete remission (CR) after DC vaccination for 83, 80.9 and 38.2 months without disease relapse.
All the patients were treated with lysate-loaded DCs (4.13×107 ± 0.27×107 cell/ injection) followed by 14 consecutive IL-2 injection. Two vaccination were subcutaneously (SC) administered in an area adjacent to the axillary lymph node at 4-week intervals.
Immunotherapy for Ovarian cancer using combination of DCs and IL-2 is safe, and this treatment induced specific immunity and potentially associated with long-term clinical response against Ovarian Cancer.
The vaccination was well tolerated. In 3 out of 10 patients.
© 2024 Immucura. All Rights Reserved
